Morgan Stanley upgrades Lam Research stock rating on NAND outlook By Investing.com

Morgan Stanley upgraded Lam Research to Overweight and lifted its price target to $331 from $293, implying 16% upside from the $284.72 share price. The firm raised its calendar 2027 forecast to $35.4 billion in revenue and $9.71 EPS, citing 59% NAND systems growth and improving NAND share gains. The article is constructive for LRCX but also notes recent weakness in chip equipment stocks after U.S. export restrictions tied to China.

Analysis

The key signal is not the upgrade itself but the rerating of NAND optionality: the market has been treating Lam as a cyclical DRAM proxy, while Morgan Stanley is implicitly saying the mix is shifting toward a more underappreciated NAND-led earnings inflection. That matters because NAND has been the cleaner operating lever for equipment intensity reacceleration; if that view is right, Lam’s multiple can expand faster than peers even if overall WFE growth stays only moderate. The 34x target multiple is aggressive for a capital goods name, but it is less about peak earnings and more about the market starting to price a multi-year share gain story rather than a one-cycle rebound.

Second-order beneficiaries are the broader semi-cap equipment complex, but the dispersion should widen. Applied Materials is the obvious relative loser if investors accept that Lam has a more favorable product-cycle mix; the premium shift from AMAT to LRCX suggests the street may be underestimating Lam’s levered exposure to incremental NAND capex while overestimating AMAT’s ability to defend share in the next leg of the cycle. On the other hand, any China tool restriction headlines are a reminder that the fastest upside in equipment can be clipped by export-control overhangs, so the trade is more vulnerable to policy shock than to demand softness.

The contrarian point is that consensus may be too linear on AI-driven demand translating into immediate WFE upside. If foundry/DRAM stay resilient but NAND only recovers gradually, Lam’s revised numbers can still be right while the stock stalls because the market has already priced a lot of the good news after multiple target raises. The timing risk is weeks to months: the next earnings print and any commentary on China exposure or NAND order momentum will decide whether this becomes a durable re-rate or just another analyst-driven squeeze.

Key Decisions for Investors

• Long LRCX vs short AMAT over the next 1-3 months: use the relative valuation gap as the expression, targeting a 5-8% spread capture if NAND momentum keeps inflecting and Lam maintains premium narrative.
• Buy LRCX on a pullback toward the low-280s with a 6-9 month horizon; risk/reward favors adding only if the stock trades at <32x forward EPS, since the current setup is already partially de-risked by multiple upgrades.
• Use LRCX call spreads rather than outright stock for event exposure into the next earnings/guidance window: upside is another 8-12%, while policy/headline risk caps outright multiple expansion.
• For a hedge, keep a small short basket in semi-cap peers most exposed to China tool restrictions; the first-order selloff in equipment names tends to be indiscriminate, but LRCX’s upgraded narrative should outperform on recovery.
• If LRCX fails to hold post-upgrade gains and trades back below prior support, fade the move with a short-term tactical short; that would imply the market is not buying the NAND reacceleration thesis and the re-rate could reverse quickly.